To minimize any chance of endogenous β‐agonist driven cancer growth or metastasis, theoretically, the “ideal” anti‐cancer β‐blocker would have high affinity, no partial agonism, and long duration of action at β2‐adrenoceptors (and for some cancers, additionally at β1 or β3‐AR). Here, ADRB3 is linked to cancer.